Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.
about
Neurocardiovascular Instability and CognitionA fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's diseaseThe "syncope and dementia" study: a prospective, observational, multicenter study of elderly patients with dementia and episodes of "suspected" transient loss of consciousness.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.Effect of acetylcholinesterase inhibitors on post-surgical complications and mortality following a hip fracture: a cohort study.Assessment and management of falls in older people.Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Effectiveness of exercise programs to reduce falls in older people with dementia living in the community: a systematic review and meta-analysis.Evaluation and management of the elderly patient presenting with cognitive complaints.Somatic comorbidities and Alzheimer's disease treatment.Medication-related falls in the elderly: causative factors and preventive strategies.The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.Adverse drug events as a cause of hospitalization in older adults.Benefits and risks of add-on therapies for Alzheimer's disease.Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis.Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Management of Gait Changes and Fall Risk in MCI and Dementia.Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study.A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.Q58775162Optimizing medications in older adults with cognitive impairment: Considerations for primary care clinicians
P2860
Q26738343-ED4DD6F0-32F4-4AF6-B81A-B8911FBFED6EQ28076715-2669F263-0AFD-49F4-88DD-AA873D8EF031Q33165491-685A69A5-5C9D-4BBA-91AF-7D809CF10509Q33165693-CA75522F-6755-42C1-BBD1-F97BF7CF065BQ33165801-F097FA28-79E9-4B5A-8408-47FEB57F4B07Q33792563-F7B84333-ABCC-43E0-9503-F584A6F28780Q33856939-899ABE6E-97CC-4843-828E-D04686447303Q34435954-81F04737-78F3-4AC9-83A9-64D5E0779274Q35006354-725E4019-BF52-4FC7-9574-D113000A5F7FQ35087891-866DEFCB-7415-4D81-8B41-9E142BE9D8CFQ35447239-9DDBBACE-6EDC-4F0A-83C8-7394138BC35FQ37199794-18D2D7C0-3AED-4A34-BC99-5F43F5FE4531Q38006976-F7504F6F-769F-4DFD-91B2-2CB73F41330DQ38083586-60F380CC-2D89-4D12-A2A1-399435E0011DQ38085222-FCE10122-8413-4F03-8454-2FC207155885Q38620338-156C4D69-58E9-4133-A371-C2402A5F8D44Q38706514-29C9269F-C7BF-40A4-BCB8-1440DC04D079Q38860696-71411A33-6FBC-4173-8A66-9E6C3B27B3D4Q38906350-7F2E66EB-C9FE-470E-BB07-62A0AA89D021Q39415447-80855AE2-53D5-417A-8E44-E0860E2AAB10Q39451476-09C5FABB-F6ED-4ED5-81CD-83CA42037A2CQ41436212-7946DFBB-56CC-4739-B1CF-65BBDBBD3CEAQ47271868-49117BF0-6A5E-4B3E-8415-2E1A788DCA1EQ47571627-23808C33-AE09-4435-9C8B-7AFA5875C697Q47955004-B516B3DF-5386-4B79-81B0-6D1A79D50DE7Q48167336-BD240D23-E7F4-4E2C-9582-C009CFCE111EQ49645966-68510397-9A49-45C3-A180-95E870606AABQ51491144-3C3055A2-F515-42B5-A74E-59BA7AF148E3Q58775162-0E594BF8-EB62-46C2-BCD4-D0C7E60DC73CQ58775224-92D778B8-27CC-4E5E-9023-9A1CFAC62D42
P2860
Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dementia medications and risk ...... randomized controlled trials.
@ast
Dementia medications and risk ...... randomized controlled trials.
@en
type
label
Dementia medications and risk ...... randomized controlled trials.
@ast
Dementia medications and risk ...... randomized controlled trials.
@en
prefLabel
Dementia medications and risk ...... randomized controlled trials.
@ast
Dementia medications and risk ...... randomized controlled trials.
@en
P2860
P50
P1476
Dementia medications and risk ...... f randomized controlled trials
@en
P2093
Dae Hyun Kim
Sarah D Berry
P2860
P304
P356
10.1111/J.1532-5415.2011.03450.X
P407
P577
2011-06-07T00:00:00Z